Literature DB >> 18383384

Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis.

Emina Savarese1, Christian Steinberg, Rahul D Pawar, Wolfgang Reindl, Shizuo Akira, Hans-Joachim Anders, Anne Krug.   

Abstract

OBJECTIVE: The detection of high titers of antibodies against small nuclear ribonucleoproteins (snRNP) is a diagnostic finding in patients in whom systemic lupus erythematosus (SLE) is suspected. Endogenous RNA molecules within snRNP trigger Toll-like receptor 7 (TLR-7) activation in B cells and dendritic cells, leading to anti-snRNP antibody production, which is associated with the development of immune complex nephritis in SLE. The purpose of this study was to investigate the role of TLR-7 in anti-snRNP antibody production and renal disease in SLE induced by an exogenous factor in the absence of genetic predisposition, using the pristane-induced murine lupus model.
METHODS: Serum autoantibodies, IgG isotypes, and cytokine levels in pristane-treated wild-type and TLR-7-deficient mice were analyzed by enzyme-linked immunosorbent assay. Histopathologic changes in mouse kidneys were determined by light immunofluorescence microscopy. Cell subsets in splenocytes and peritoneal lavage cells from the mice were examined by flow cytometry.
RESULTS: We found that anti-snRNP antibody production induced by pristane treatment was entirely dependent on the expression of TLR-7, whereas anti-double-stranded DNA antibody production was not affected by a lack of TLR-7. Impaired anti-snRNP antibody production in TLR-7-deficient mice was paralleled by lower levels of glomerular IgG and complement deposits, as well as less severe glomerulonephritis.
CONCLUSION: TLR-7 is specifically required for the production of RNA-reactive autoantibodies and the development of glomerulonephritis in pristane-induced murine lupus, a model of environmentally triggered SLE in the absence of genetic susceptibility to autoimmunity. Specific interference with TLR-7 activation by endogenous TLR-7 ligands may therefore be a promising novel strategy for the treatment of SLE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383384     DOI: 10.1002/art.23407

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  56 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Toll-like receptors and lupus nephritis.

Authors:  Fabrizio Conti; Francesca Romana Spinelli; Cristiano Alessandri; Guido Valesini
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

Review 3.  Translating nucleic acid-sensing pathways into therapies.

Authors:  Tobias Junt; Winfried Barchet
Journal:  Nat Rev Immunol       Date:  2015-08-21       Impact factor: 53.106

4.  TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus.

Authors:  Lukas Bossaller; Anette Christ; Karin Pelka; Kerstin Nündel; Ping-I Chiang; Catherine Pang; Neha Mishra; Patricia Busto; Ramon G Bonegio; Reinhold Ernst Schmidt; Eicke Latz; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2016-06-27       Impact factor: 5.422

5.  Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation.

Authors:  Purvi Mande; Bahar Zirak; Wei-Che Ko; Keyon Taravati; Karen L Bride; Tia Y Brodeur; April Deng; Karen Dresser; Zhaozhao Jiang; Rachel Ettinger; Katherine A Fitzgerald; Michael D Rosenblum; John E Harris; Ann Marshak-Rothstein
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

6.  Suppression of systemic autoimmunity by the innate immune adaptor STING.

Authors:  Shruti Sharma; Allison M Campbell; Jennie Chan; Stefan A Schattgen; Gregory M Orlowski; Ribhu Nayar; Annie H Huyler; Kerstin Nündel; Chandra Mohan; Leslie J Berg; Mark J Shlomchik; Ann Marshak-Rothstein; Katherine A Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

Review 7.  Immunopathology of lupus nephritis.

Authors:  Hans-Joachim Anders; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

8.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

Review 9.  Regulation of autoreactive B cell responses to endogenous TLR ligands.

Authors:  Ana Maria Avalos; Liliana Busconi; Ann Marshak-Rothstein
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus.

Authors:  Donna L Thibault; Kareem L Graham; Lowen Y Lee; Imelda Balboni; Paul J Hertzog; Paul J Utz
Journal:  Arthritis Res Ther       Date:  2009-07-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.